Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert Youssef

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Journal of Neuro-Oncology|June 8, 2026
Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional surveyTyler A Lanman, L Nicolas Gonzalez Castro, Haley K Perlow, et al.
Journal of Neuro-Oncology|October 21, 2024
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial designEthan A Wetzel, Amin I Nohman, Annie L Hsieh, et al.
Clinical and Translational Radiation Oncology|December 4, 2023
Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrenceSebastian M Christ, Gilbert Youssef, Shyam K Tanguturi, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Neuro-Oncology|November 19, 2022
Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticityJamie A Dean, Shyam K Tanguturi, Daniel Cagney, et al.
Neuro-Oncology Practice|February 7, 2025
<i>G</i>lioma <i>r</i>esource <i>o</i>utreach <i>w</i>ith <i>s</i>upport: A program to identify and initiate supportive care interventions for unmet needs among adult lower-grade glioma patientsRachel Garcia Fox, Ugonma N Chukwueke, Timothy Sannes, et al.
Neuro-Oncology Advances|August 9, 2023
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppressionDavy Deng, Lubna Hammoudeh, Gilbert Youssef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed GlioblastomaMary Jane Lim-Fat, J Bryan Iorgulescu, Rifaquat Rahman, et al.
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Neuro-Oncology|June 8, 2026
Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional surveyTyler A Lanman, L Nicolas Gonzalez Castro, Haley K Perlow, et al.
Journal of Neuro-Oncology|October 21, 2024
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial designEthan A Wetzel, Amin I Nohman, Annie L Hsieh, et al.
Clinical and Translational Radiation Oncology|December 4, 2023
Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrenceSebastian M Christ, Gilbert Youssef, Shyam K Tanguturi, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Neuro-Oncology|November 19, 2022
Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticityJamie A Dean, Shyam K Tanguturi, Daniel Cagney, et al.
Neuro-Oncology Practice|February 7, 2025
<i>G</i>lioma <i>r</i>esource <i>o</i>utreach <i>w</i>ith <i>s</i>upport: A program to identify and initiate supportive care interventions for unmet needs among adult lower-grade glioma patientsRachel Garcia Fox, Ugonma N Chukwueke, Timothy Sannes, et al.
Neuro-Oncology Advances|August 9, 2023
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppressionDavy Deng, Lubna Hammoudeh, Gilbert Youssef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed GlioblastomaMary Jane Lim-Fat, J Bryan Iorgulescu, Rifaquat Rahman, et al.
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Pageof 4